147 related articles for article (PubMed ID: 37432984)
1. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
Black LE; Longo JF; Anderson JC; Carroll SL
Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
[TBL] [Abstract][Full Text] [Related]
4. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents.
González-Muñoz T; Kim A; Ratner N; Peinado H
Clin Cancer Res; 2022 Aug; 28(15):3185-3195. PubMed ID: 35446392
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
6. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
[TBL] [Abstract][Full Text] [Related]
7. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Young ED; Belousov R; Zhang Y; Lopez G; Lusby K; Kivlin C; Demicco EG; Creighton CJ; Lazar AJ; Pollock RE; Lev D
Clin Cancer Res; 2012 May; 18(9):2545-57. PubMed ID: 22407831
[TBL] [Abstract][Full Text] [Related]
8. Decorin suppresses stemness and migration potential of malignant peripheral nerve sheath tumor through inhibiting epidermal growth factor receptor signaling.
Jia X; Chen L; Yu C
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167181. PubMed ID: 38653361
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
[TBL] [Abstract][Full Text] [Related]
10. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
11. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
Qin W; Godec A; Zhang X; Zhu C; Shao J; Tao Y; Bu X; Hirbe AC
Cancer Med; 2019 Sep; 8(11):5232-5241. PubMed ID: 31278855
[TBL] [Abstract][Full Text] [Related]
12. Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Ali ES; Krecmerova M; Aguilar JMH; Alt J; Peters DE; Zhao L; Wu Y; Nuha N; Asara JM; Staedtke V; Pratilas CA; Majer P; Rais R; Ben-Sahra I; Slusher BS
Mol Cancer Ther; 2023 Dec; 22(12):1390-1403. PubMed ID: 37616542
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract][Full Text] [Related]
14. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
16. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
17. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
[TBL] [Abstract][Full Text] [Related]
18. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract][Full Text] [Related]
19. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
[TBL] [Abstract][Full Text] [Related]
20. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
